SynthesisInflammatory bowel diseases2025
Gut Mycobiome in Inflammatory Bowel Disease: A Systematic Review of Case-Control Studies.
Synthesis in Inflammatory bowel diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Shared CD4+ T cell receptor specificity groups in Crohn's disease and ulcerative colitis.JCI insight · 2026Article
- The Gut Mycobiome in Inflammatory Bowel Disease: ReframingJournal of fungi (Basel, Switzerland) · 2026Review
- Expansion resistance against genotoxicFrontiers in microbiology · 2026Article
- Gut microbiota and inflammatory bowel disease: mechanisms, clinical implications, and future directions.Molecular biology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe bacterial composition of the microbiome in inflammatory bowel disease (IBD) has been the focus of substantial interest. In contrast, the fungal part of the microbiome, the mycobiome, has only rarely been investigated-although anti-Saccharomyces cerevisiae antibodies, an antibody against fungal mannan, have been known for years as a biomarker for Crohn's disease (CD), but not for ulcerative colitis (UC).
methodsA systematic review of case-control studies on the human gut mycobiome in IBD was conducted using searches in EMBASE and MEDLINE.
resultsTwenty-seven studies, with a total of 1406 IBD patients and 1060 controls were identified. The differences in alpha diversity varied across studies and were related to geography, whereas differences in beta diversity between cases and controls were found in a large majority of the studies. Overall, the results were inconsistent at different taxonomic levels, and the studied populations were heterogeneous, as were the methodological approaches. The most consistent finding was an increase of Candida for both CD and UC and of Malassezia in CD, where it was often linked to a decrease of Saccharomyces.
conclusionsThe mycobiome is altered in IBD, as differences in beta diversity were found between cases and controls consistently. Future studies should carefully standardize every step from sample collection through analysis and data processing, allowing external validation of findings. Inclusion of treatment naïve patients and symptomatic controls could further advance this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.